Ikena Oncology Inc. (NASDAQ: IKNA)
$1.72
-0.0050 ( -0.29% ) 0.4K
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Market Data
Open
$1.72
Previous close
$1.73
Volume
0.4K
Market cap
$84.45M
Day range
$1.66 - $1.73
52 week range
$1.02 - $6.80
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 55 | May 13, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |
def | Proxies and info statements | 5 | Apr 26, 2024 |
10-k | Annual reports | 118 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 05, 2024 |
3 | Insider transactions | 2 | Mar 05, 2024 |
8-k | 8K-related | 17 | Feb 21, 2024 |
4 | Insider transactions | 1 | Feb 02, 2024 |
4 | Insider transactions | 1 | Feb 02, 2024 |
4 | Insider transactions | 1 | Feb 02, 2024 |